Immunovant, Inc. IMVT United States — United States – State
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CurrentStateAndLocalTaxExpenseBenefit.
The official record: Immunovant, Inc.’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immunovant, Inc.'s united states — united states – state.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immunovant, Inc.'s united states — united states – state?
- Immunovant, Inc. (IMVT) reported united states — united states – state of $53.75K in Q1 2026.
- How has Immunovant, Inc.'s united states — united states – state changed year-over-year?
- Immunovant, Inc.'s united states — united states – state increased by 1854.5% year-over-year, from $2.75K to $53.75K.
- What is the long-term trend for Immunovant, Inc.'s united states — united states – state?
- Over 4 years (2022 to 2026), Immunovant, Inc.'s united states — united states – state has grown at a 282.9% compound annual growth rate (CAGR), from $1K to $215K.
- What does united states — united states – state mean?
- Captures the income tax expense or benefit levied by individual U.S. state jurisdictions on the company's domestic segment operations. This metric reflects the localized tax burden imposed by state-level regulations. Monitoring this helps assess the geographic tax efficiency of the company's domestic footprint.